Pemetrexed Disodium

• A Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy in Participants with St… Ended
  2023-508372-10-00 Phase II 9 countries Bristol-Myers Squibb Services Unlimited Company
• A Randomized, Open-label Phase 3 Study of Combination Amivantamab and CarboplatinPemetrexed Therapy, Compared with Carboplatin-Pemetrexed, i… Ended
  2023-506033-29-00 Phase III 8 countries Janssen - Cilag International
• A Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy with or without Pembrolizumab (LIBRETTO-431) Ended
  2023-506783-14-00 Phase III 7 countries Eli Lilly & Co.
• GEN1042 Trial of Safety and Anti-tumor Activity in Subjects with Malignant Solid Tumors Ended
  2023-508526-10-00 Phase I (FiH) 5 countries Genmab A/S
• A Study of Durvalumab Before and After Surgery for Patients with Operable Non-Small Cell Lung Cancer. Ended
  2023-509576-42-00 Phase III 9 countries AstraZeneca AB
• Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lun… Ended
  2023-505981-26-00 Phase III 9 countries F. Hoffmann-La Roche AG
• Trial to assess the safety and preliminary efficacy of GEN1055 on malignant solid tumors as monotherapy and as combination therapy. Ended
  2023-507049-28-00 Phase I (FiH) 1 country Genmab A/S
• A Phase 1b/2 Study of BMS-986442 with Nivolumab with or without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer Ended
  2022-503108-26-00 Phase I (FiH) 3 countries Bristol-Myers Squibb Services Unlimited Company
• Substudy to test investigational agents with pembrolizumab in combination with chemotherapy in treatment-naïve NSCLC in a rolling arm design Ended
  2023-506932-33-00 Phase II 4 countries Merck Sharp & Dohme LLC
• A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and N… Ended
  2022-501987-16-00 Phase III 2 countries Incyte Corp.
• A study of nivolumab and ipilimumab in untreated patients with stage 3 NSCLC that is unable or not planned to be removed by surgery Ended
  2022-502886-71-00 Phase III 11 countries Bristol Myers Squibb International Corporation
• Phase 3 Study of Pembrolizumab with Maintenance Olaparib or Maintenance Pemetrexed in 1L Metastatic Nonsquamous NSCLC Ended
  2023-509774-40-00 Phase III 6 countries Merck Sharp & Dohme LLC
• Study of efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab in previously untreated l… Ended
  2024-511490-29-00 Phase III 2 countries Novartis Pharma AG
• Study of durvalumab/placebo + chemoradiation therapy in Patients with Unresectable, Locally Advanced Non-small Cell Lung Cancer Ended
  2024-515321-29-00 Phase III 2 countries AstraZeneca AB
• A Phase 2 Study of BMS-986315 and Nivolumab in Combination with Chemotherapy in Participants with First-line Stage IV or Recurrent NSCLC Ended
  2022-503007-22-00 Phase II 5 countries Bristol-Myers Squibb Services Unlimited Company

Showing 25–39 of 39 trials